Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-28

Study Completion Date

2018-11-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective, open label, muti-center study evaluates the use of Nano-Pulse Stimulation (NPS) in the treatment of Sebaceous Hyperplasia (SH) lesions less than 2.5mm in size.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nano-Pulse Stimulation (NPS) in Sebaceous Hyperplasia Optimization Study

NCT04253418

Sebaceous Hyperplasia Skin Abnormalities Skin Lesion

TERMINATED NA

Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions

NCT04539886

Skin Lesion Skin Abnormalities Sebaceous Hyperplasia

COMPLETED NA

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466

Common Warts

COMPLETED NA

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

NCT02956317

Hypertrophic Scar

COMPLETED PHASE1/PHASE2

CellFX System for the Treatment of Cutaneous Non-Genital Warts

NCT04554394

Warts Warts Hand Verruca

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is designed with each subject serving as his or her own control. A total of up to 75 subjects with 2-5 qualifying SH lesions will be enrolled and treated with either a 1.5-mm x 1.5-mm or 2.5-mm x 2.5-mm tip. All treated lesions will receive at least one NPS treatment and evaluated at 30 days for lesion clearance. Initial lesions scored as Not Clear or Partially Clear may undergo a second NPS treatment. All subjects will have their lesions evaluated at 60 days post-primary or secondary treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Lesion Skin Abnormalities Sebaceous Hyperplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NPS Treated SH Lesion

Nano-Pulse Stimulation Device using pre-defined energy protocol

Group Type EXPERIMENTAL

Nano-Pulse Stimulation Device

Intervention Type DEVICE

NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nano-Pulse Stimulation Device

NPS utilizes a timed series of low energy, high voltage nanosecond (billionth of a second) pulses which are applied directly to targeted tissue using small microneedles. NPS energy induces cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles and initiate regulated cell death.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females
* Presents with at least 2 and up to 5 clinically visible SH lesions
* Understands that 1 lesion will remain untreated to act as a reference
* Lesions must measure no greater than 2.5 x 2.5 at the outside margin
* Wishes to have at least 1 and perhaps 2 NPS treatments to each study lesion
* Selection of the non-treated reference lesion will be randomly identified
* Willing to return for 4 or 5 total study visits at specified intervals over 60 or 90 days
* Agrees to photographic or other image capture methods of both the treated and untreated lesions.
* Agrees to avoid any other treatment to the NPS treated and untreated SH lesions until the end of the NPS study
* Has no evidence of active infection in the designated tissue prior to treatment and reports no infection within 90 days
* Is not allergic to Lidocaine or Lidocaine-like products

Exclusion Criteria

* Presence of Implantable electronic devices that cannot be removed. e.g., pacemaker or automatic defibrillator
* Taking medications prescribed for cardiac arrhythmia at any time within 6 months prior to exposure to the NPS device
* SH lesions are located within the eye orbit or on the nose
* Active infection or history of infection in designated test area within 90 days prior to study initiation
* Use of oral steroid and/or retinoid use within the last 12 months
* Prior treatment to the identified SH lesions targeted for the study which occurred within 6 months prior to study start
* Is known to be immune-compromised and/or received immunosuppressant therapy within 6 months prior to study start
* Taking blood thinning medications
* Has Insulin dependent diabetes
* Is known to be pregnant or lactating female

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No